source
- Argenx halts Phase 3 Sjögren's trial as celiac disease data brings mixed resultsArgenx disclosed on Thursday that it is ending its Phase 3 trial in Sjögren's syndrome after the study failed to meet its primary endpoint. The decision came alongside the release of encouraging r…
- CMS proposes changes to curb 340B drug discount program’s costly subsidies to safety-net hospitalsCasey B. Mulligan, chief economist and chief regulatory officer at HHS, wrote an opinion piece outlining a major flaw in the 340B drug discount program. The program, created in 1992, gives steep di…